Biotechnology company Macrogen reported on Tuesday the launch of a contract to become the exclusive buyer of exosome isolation kits from Exosome Plus.

Under the new one year supply agreement, Exosome Plus will exclusively supply its high-efficiency exosome isolation kit 'Exo2DTM' to Macrogen.

As part of the agreement, Macrogen may sell the isolation kits to third parties across its domestic and global distribution network as well as use the isolation kits for its 'exosomal RNA and DNA sequencing service' for the research market to improve production efficiency and service stability.

Additionally, the two companies have signed an MOU for the joint development of exosome-based diagnostic and treatment solutions.

The MOU allows the companies to jointly develop exosome-based biomarkers for early diagnosis, the development of therapeutic agents, applied uses in drug delivery carriers, vaccines and cosmetics, cooperative education and training to foster the manpower necessary for the development of pharmaceuticals as well as the joint use of infrastructure, including equipment and facilities.

From 25 April 2019 to 28 April 2019, the companies will participate in the 2019 meeting of the International Society for Extracellular Vesicles (ISEV) in Kyoto, Japan, will jointly present their exosome isolation and nucleic acid analysis technologies as well as engage in joint marketing for the development of domestic and overseas markets.